ANI Pharmaceuticals (NASDAQ:ANIP) Rating Lowered to “Hold” at Zacks Research

ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.

ANIP has been the topic of a number of other reports. Guggenheim lifted their target price on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $107.33.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $78.01 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. The firm’s 50-day moving average is $77.29 and its two-hundred day moving average is $80.48. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50. The company has a market capitalization of $1.77 billion, a PE ratio of 19.75 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. During the same period in the previous year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Analysts predict that ANI Pharmaceuticals will post 7.73 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $78.16, for a total value of $39,080.00. Following the sale, the vice president directly owned 78,390 shares of the company’s stock, valued at approximately $6,126,962.40. The trade was a 0.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Thomas Andrew Rowland sold 459 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president directly owned 38,271 shares in the company, valued at $3,031,445.91. This trade represents a 1.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 100,564 shares of company stock worth $7,800,862. Insiders own 8.10% of the company’s stock.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Divisadero Street Capital Management LP purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $21,454,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at approximately $1,597,000. Apis Capital Advisors LLC raised its stake in shares of ANI Pharmaceuticals by 28.1% in the 3rd quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after acquiring an additional 36,000 shares during the period. Oliver Luxxe Assets LLC purchased a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at approximately $1,823,000. Finally, Thrivent Financial for Lutherans raised its stake in shares of ANI Pharmaceuticals by 363.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 58,027 shares of the specialty pharmaceutical company’s stock valued at $5,315,000 after acquiring an additional 45,516 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.